BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31658127)

  • 1. Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia.
    Zhou K; Wahed AS; Cooper S; Di Bisceglie AM; Fontana RJ; Ghany MG; Khalili M; Lok AS; Perrillo R; Lee WM; Lau DTY; Sterling R; Janssen HLA; Terrault NA
    Am J Gastroenterol; 2019 Nov; 114(11):1753-1763. PubMed ID: 31658127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
    Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
    Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection.
    Papatheodoridis GV; Chrysanthos N; Hadziyannis E; Cholongitas E; Manesis EK
    J Viral Hepat; 2008 Jun; 15(6):434-41. PubMed ID: 18194171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection.
    Manesis EK; Papatheodoridis GV; Sevastianos V; Cholongitas E; Papaioannou C; Hadziyannis SJ
    Am J Gastroenterol; 2003 Oct; 98(10):2261-7. PubMed ID: 14572577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers.
    Assy N; Beniashvili Z; Djibre A; Nasser G; Grosovski M; Nseir W
    World J Gastroenterol; 2009 Jun; 15(24):3025-31. PubMed ID: 19554656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
    Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
    Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
    Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
    Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
    Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
    World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline HBsAg levels associated with HBsAg loss in HBeAg-negative chronic hepatitis B infection with persistently normal alanine aminotransferase.
    Chen L; Shi J; Lu Z; Ye Y; Zhou X; Tan Y
    Clin Res Hepatol Gastroenterol; 2019 Jun; 43(3):310-316. PubMed ID: 30528063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers.
    Park H; Lee JM; Seo JH; Kim HS; Ahn SH; Kim DY; Han KH; Chon CY; Park JY
    Liver Int; 2012 May; 32(5):796-802. PubMed ID: 22128792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
    Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
    J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do the circulating Pre-S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection?
    Cavallone D; Ricco G; Oliveri F; Colombatto P; Moriconi F; Coco B; Romagnoli V; Salvati A; Surace L; Bonino F; Brunetto MR
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1406-1416. PubMed ID: 32390175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.
    Fung J; Seto WK; Wong DK; Lai CL; Yuen MF
    Liver Int; 2015 Mar; 35(3):854-9. PubMed ID: 24840542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
    Chun HS; Papatheodoridis GV; Lee M; Lee HA; Kim YH; Kim SH; Oh YS; Park SJ; Kim J; Lee HA; Kim HY; Kim TH; Yoon EL; Jun DW; Ahn SH; Sypsa V; Yurdaydin C; Lampertico P; Calleja JL; Janssen H; Dalekos GN; Goulis J; Berg T; Buti M; Kim SU; Kim YJ
    J Hepatol; 2024 Jan; 80(1):20-30. PubMed ID: 37734683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2012 Jan; 55(1):68-76. PubMed ID: 21858846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal observation of viral load changes in untreated HBeAg negative chronic hepatitis B.
    Croagh CM; Bell SJ; Chen RY; Locarnini S; Desmond PV
    Acta Gastroenterol Belg; 2013 Sep; 76(3):275-81. PubMed ID: 24261020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
    Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Demographic characteristics and associated influencing factors in treated patients with chronic hepatitis B with hypoviremia : a single-center retrospective cross-sectional study].
    Li T; Kong Y; Liu YY; Liu TF; Ma AD; Li LQ; Pei ZY; Zhang LY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):42-48. PubMed ID: 36948848
    [No Abstract]   [Full Text] [Related]  

  • 20. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B.
    Duan M; Chi X; Xiao H; Liu X; Zhuang H
    Hepatol Int; 2021 Apr; 15(2):318-327. PubMed ID: 33638049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.